Sustained renal response to mycophenolate mofetil and CNI taper promotes survival in liver transplant patients with CNI-related renal dysfunction

Digestive Diseases and Sciences

Volumn 56, Issue 1, 2011, Pages 244-251

  Kornberg, A ^a,c   Kupper B ^b   Thrum, K ^b   Krause, B ^c   Buchler P ^a   Kornberg, J ^c   Sappler, A ^c   Altendorf Hofmann, A ^c   Wilberg, J ^c   Friess, H ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Zentralklinikum Bad Berka ^*  (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Calcineurin inhibitor; Liver transplantation; Long term survival; Mycophenolate mofetil; Renal function

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN A; DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL;

ADULT; CALCINEURIN; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOPHENOLIC ACID; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TACROLIMUS;

EID: 79151482760     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-010-1386-z     Document Type: Article

References (41)

1. NC Fisher PG Nightingale BK Gunson GW Lipkin JM Neuberger 1998 Chronic renal failure following liver transplantation: a retrospective analysis Transplantation 66 59 66 1:STN:280:DyaK1czktlCitQ%3D%3D 10.1097/00007890- 199807150-00010 9679823
2. TA Gonwa ML Mai LB Melton SR Hays RM Goldstein MF Levy GB Klintmalm 2001 End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment Transplantation 72 1934 1939 1:STN:280:DC%2BD38%2FltFKmtA%3D%3D 10.1097/00007890-200112270-00012 11773892
3. AO Ojo PJ Held FK Port RA Wolfe AB Leichtman EW Young, et al. 2003 Chronic renal failure after transplantation of a nonrenal organ N Engl J Med 349 931 940 1:CAS:528:DC%2BD3sXntFeitr4%3D 10.1056/NEJMoa021744 12954741
4. The US Multicenter FK506 Liver Study Group 1994 A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation N Engl J Med 331 1110 1115 10.1056/NEJM199410273311702
5. A Wilkinson PT Pham 2005 Kidney dysfunction in the recipients of liver transplants Liver Transpl 11 S 47 51 10.1002/lt.20618
6. JM Campistol SH Sacks 2000 Mechanisms of nephrotoxicity Transplantation 69 SS5 SS10 1:CAS:528:DC%2BD3cXlsV2ltbY%3D 10910256
7. DR Davies I Bittmann J Pardo 2000 Histopathology of calcineurin inhibitor-induced nephrotoxicity Transplantation 69 Suppl SS11 SS13 1:CAS:528:DC%2BD3cXlsV2ltbc%3D 10910257
8. O Bestard JM Cruzado JM Grinyó 2005 Calcineurin-inhibitor-sparing immunosuppressive protocols Transpl Proc 37 3729 3732 1:CAS:528:DC%2BD28Xktl2q 10.1016/j.transproceed.2005.09.129
9. AC Allison EM Eugui 2000 Mycophenolate mofetil and its mechanisms of action Immunopharmacology 47 85 111 1:CAS:528:DC%2BD3cXktlKkt7o%3D 10.1016/S0162-3109(00)00188-0 10878285
10. AC Allison EM Eugui 2005 Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection Transplantation 80 181 190 10.1097/01.tp.0000186390.10150.66
11. N Roos N Poulalhon D Farge I Madelaine A Mauviel F Verrecchia 2007 In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil J Pharmacol Exp Ther 321 583 589 1:CAS:528: DC%2BD2sXltFehtbg%3D 10.1124/jpet.106.117051 17272676
12. SI van Leuven JJ Kastelein AC Allison MR Hayden ES Stroes 2006 Mycophenolate mofetil (MMF): firing at the atherosclerotic plaque from different angles? Cardiovasc Res 69 341 347 10.1016/j.cardiores.2005.09.018 16289002
13. JM Boots MH Christiaans JP van Hooff 2004 Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk Drugs 64 2047 2073 1:CAS:528:DC%2BD2cXptFGrtL4%3D 10.2165/00003495-200464180-00004 15341497
14. W Land F Vincenti 2005 Toxicity-sparing protocols using mycophenolate mofetil in renal transplantation Transplantation 80 Suppl S221 S243 1:CAS:528:DC%2BD2MXhtFGhsL7I 10.1097/01.tp.0000186386.13597.cb 16251855
15. G Offermann 2004 Immunosuppression for long-term maintenance of renal allograft function Drugs 64 1325 1338 1:CAS:528:DC%2BD2cXmsVOhtLw%3D 10.2165/00003495-200464120-00005 15200347
16. RH Wiesner JS Shorr BJ Steffen AH Chu RD Gordon JR Lake 2005 Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C Liver Transpl. 11 750 759 10.1002/lt.20453 15973716
17. RH Wiesner BJ Steffen KM David AH Chu RD Gordon JR Lake 2006 Mycophenolate mofetil use is associated with decreased risk of late acute rejection in adult liver transplant recipients Am J Transplant 6 1609 1616 1:CAS:528:DC%2BD28XnsFGgtrw%3D 10.1111/j.1600-6143.2006.01382.x 16827861
18. SF Stewart M Hudson D Talbot D Manas CP Day 2001 Mycophenolate mofetil monotherapy in liver transplantation Lancet 357 609 610 1:CAS:528: DC%2BD3MXhsVKltbc%3D 10.1016/S0140-6736(00)04065-4 11558493
19. HJ Schlitt A Barkmann KH Böker HH Schmidt N Emmanouilidis J Rosenau, et al. 2001 Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study Lancet 357 587 591 1:CAS:528:DC%2BD3MXhsVKltbg%3D 10.1016/S0140-6736(00)04055-1 11558484
20. KD Fairbanks PJ Thuluvath 2004 Mycophenolate mofetil monotherapy in liver transplant recipients: a single center experience Liver Transpl 10 1189 1194 10.1002/lt.20210 15350013
21. GP Pageaux L Rostaing Y Calmus C Duvoux C Vanlemmens J Hardgwissen, et al. 2006 Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation Liver Transpl 12 1755 1760 10.1002/lt.20903 17133564
22. DJ Reich PA Clavien EE Hodge MMF Renal Dysfunction after Liver Transplantation Working Group 2005 Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results Transplantation 80 18 25 1:CAS:528:DC%2BD2MXlvVylt7s%3D 10.1097/01.TP.0000165118.00988.D7 16003228
23. S Beckebaum VR Cicinnati CG Klein E Brokalaki Z Yu M Malago, et al. 2004 Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study Transpl Proc 36 2671 2674 1:CAS:528:DC%2BD2cXhtFGhtLbE 10.1016/j.transproceed. 2004.10.008
24. ML Raimondo L Dagher GV Papatheodoridis N Rolando DW Patch BR Davidson, et al. 2003 Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation Transplantation 75 186 190 1:CAS:528:DC%2BD3sXmtVWmsA%3D%3D 10.1097/01.TP.0000041702.31262.CD 12548120
25. M Cantarovich GN Tzimas J Barkun M Deschênes E Alpert J Tchervenkov 2003 Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction Transplantation 76 98 102 1:CAS:528:DC%2BD3sXlsVyms7c%3D 10.1097/01.TP. 0000054367.57978.4C 12865793
26. A Kornberg B Küpper M Hommann J Scheele 2005 Introduction of MMF in conjunction with stepwise reduction of calcineurin inhibitor in stable liver transplant patients with renal dysfunction Int Immunopharmacol 5 141 146 1:CAS:528:DC%2BD2cXhtVKls73I 10.1016/j.intimp.2004.09.018 15589474
27. A Jain R Vekatramanan B Eghtesad M Gadomski R Mohanka A Marcos J Fung 2005 Long-term outcome of adding mycophenolate mofetil to tacrolimus for nephrotoxicity following liver transplantation Transplantation 27 80 859 864 10.1097/01.TP.0000173994.63299.63
28. VR Cicinnati Z Yu CG Klein GC Sotiropoulos F Saner M Malagó A Frilling, et al. 2007 Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients-assessment of renal and allograft function, cardiovascular risk factors and immune monitoring Aliment Pharmacol Ther 26 1195 1208 1:CAS:528: DC%2BD2sXhtlyrsbbE 10.1111/j.1365-2036.2007.03466.x 17944734
29. M Biselli G Vitale A Gramenzi A Riili S Berardi C Cammà, et al. 2009 Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant Clin Transpl 23 191 198 10.1111/j.1399-0012. 2009.00965.x
30. JM Tredger NW Brown J Adams CE Gonde A Dhawan M Rela N Heaton 2004 Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range Liver Transpl 10 492 502 10.1002/lt.20124 15048791
31. D DuBay RJ Smith KG Qiu G Levy L Lilly G Therapondos 2008 Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens Liver Transpl 14 651 659 10.1002/lt.21429 18433069
32. H Persson G Nordén I Karlberg S Friman 1994 Glomerular filtratio rate after liver transplantation with a low-dose cyclosporin protocol Transpl Int 7 172 176 1:STN:280:DyaK2czjvVGjsQ%3D%3D 10.1111/j.1432-2277.1994.tb01286.x 8060465
33. SM Flechner J Kobashigawa G Klintmalm 2008 Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity Clin Transpl 22 1 15 10.1111/j.1399-0012.2008.00859.x
34. PC Baer S Gauer IA Hauser JE Scherberich H Geiger 2000 Effects of mycophenolic acid on human renal proximal and distal tubular cells in vitro Nephrol Dial Transpl 15 184 190 1:CAS:528:DC%2BD3cXhtV2lt74%3D 10.1093/ndt/15.2.184
35. I Dubus B Vendrely I Christophe JP Labouyrie Y Delmas J Bonnet C Combe 2002 Mycophenolic acid antagonizes the activation of cultured human mesangial cells Kidney Int 62 857 867 1:CAS:528:DC%2BD38XntFSrsr0%3D 10.1046/j.1523-1755. 2002.00514.x 12164867
36. BJ Nankivell MD Wavamunno RJ Borrows M Vitalone CL Fung RD Allen, et al. 2007 Mycophenolate mofetil is associated with altered expression of chronic renal transplant histology Am J Transpl 7 366 376 1:CAS:528:DC%2BD2sXhvFClsbY%3D 10.1111/j.1600-6143.2006.01633.x
37. MKh Hong PW Angus RM Jones RB Vaughan PJ Gow 2005 Predictors of improvement in renal function after calcineurin inhibitor withdrawal for post-liver transplant renal dysfunction Clin Transpl 19 193 198 10.1111/j.1399-0012.2004.00317.x
38. D Cattaneo F Gaspari S Ferrari N Stucchi L Del Priore N Perico E Gotti G Remuzzi 2001 Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients Clin Transpl 15 402 409 1:STN:280: DC%2BD3MnpvFaisA%3D%3D 10.1034/j.1399-0012.2001.150607.x
39. R Borrows G Chusney A James J Stichbury J Van Tromp T Cairns, et al. 2005 Determinants of mycophenolic acid levels after renal transplantation Ther Drug Monit 27 442 450 1:CAS:528:DC%2BD2MXmsV2ju7k%3D 10.1097/01.ftd.0000167885.17280. 6f 16044100
40. R Kashyap G Tsoulfas C Mack M Williamson P Batzold A Bozorgzadeh 2007 Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil Liver Transpl 13 791 796 10.1002/lt.21146 17538999
41. B Kaplan 2006 Mycophenolic acid trough level monitoring in solid organ transplant recipients treated with mycophenolate mofetil: association with clinical outcome Curr Med Res Opin 22 2355 2364 1:CAS:528:DC%2BD2sXhsVOlt7s%3D 10.1185/030079906X148481 17257450